الفهرس 
Review of literatureOnly 14 pages are availabe for public view
 |  | from | 191 |  |  |
| | | from | 191 | | |
Abstract
- This study was conducted on eighty eight Egyptian patients with documented CHC infection anti-HCV seropositive and detectable (HCV-RNA)
- The aim of this study Il-38 gene polymorphism as pre-treatment predicator of therapy – induced viral the potential relation between Il-28 gene polymorphism and the other host factors that may influence the response to treatment like age, gender, stage of fibrosis, BMI,, ALT levels, as well as HCV RNA load.
- The indication of IL-78 genotypes heralds the era of genomic medicine in HCV and opens the door for understanding HCV clearance. IL-28B genotyping could provide important and independent information about a patient’s like hood of achieving a sustained virological response and helping these patients and their doctors to decide whether to initiate therapy or wait until directly acting anti-viral become available. HCV treatment should not be withheld based solely on IL-28B genotype and the coming months and years may provide a new relevant host and viral predictors of response.